Home › Ovarian Cancer › Oregon › Eugene
Ovarian Cancer clinical trials in Eugene, OR
10 studies for Ovarian Cancer are looking for participants at sites in and around Eugene (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RecruitingPhase 3
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010), Eugene
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
RecruitingPhase 3
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8000), Eugene
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RecruitingPhase 3
- USO - Oncology Associates of Oregon, P. C., Eugene
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
- USOR Oncology Associates of Oregon, P.C., Eugene
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RecruitingPhase 2
- Site 0316 - Willamette Valley Cancer Institute/Oncology Associates of Oregon, Eugene
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
RecruitingPhase 2/3
- Oncology Associates of Oregon, P.C., Eugene
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RecruitingPhase 2
- Oncology Associates of Oregon, P.C. /ID# 275006, Eugene
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RecruitingPhase 3
- Oncology Associates of Oregon, P.C., Eugene
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
RecruitingPhase 2
- Willamette Valley Cancer Institute and Research Center /ID# 277714, Eugene
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RecruitingPhase 2
- 517, Eugene
About Ovarian Cancer
Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. The ovaries are a pair of female reproductive glands that make eggs and female hormones.
More about Ovarian Cancer on MedlinePlus
Ovarian Cancer trials in other cities
- Houston, TX90 studies
- New York City, NY75 studies
- Boston, MA62 studies
- Los Angeles, CA53 studies
- Nashville, TN50 studies
- Arlington, VA47 studies
- Philadelphia, PA47 studies
- Columbus, OH39 studies
- St. Louis, MO37 studies
- Chicago, IL36 studies
- San Antonio, TX33 studies
- Pittsburgh, PA32 studies
Other studies in Eugene
- Non-Small Cell Lung Cancer11 studies
- Endometrial Cancer8 studies
- Metastatic Cancer6 studies
- Breast Cancer6 studies
- Cancer (all types)6 studies
- Multiple Myeloma6 studies
- Chronic Lymphocytic Leukemia6 studies
- Drug Use and Addiction5 studies
- Obesity4 studies
- Macular Degeneration4 studies
- Lung Cancer4 studies
- Overweight3 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.